“Milton Keynes is a ‘New City’ with a (relatively) ‘New’ hospital. Phase 1 was opened in January 1984, at which time I joined the commissioning team having previously trained at Northampton General Hospital. We provide a diagnostic and therapeutic haematology service to the growing inpatient and PCT client base, the expanding population ensures that workload increases steadily year on year. Our “bread and butter” workload is currently in excess of 700 FBC’s per day.
In its infancy, Sysmex instruments were distributed through a Milton Keynes based company LEP Scientific; I almost left the NHS to work as a rep for them in the late 80’s!
Our first Sysmex analyser was a BCT coagulation machine, originally placed by locally based Behring Diagnostics and subsequently taken over by Sysmex. This machine was soon replaced by a CA1500 (augmented in time to two!) and our relationship proper began in earnest.
When our mainline haematology analysers (two Bayer Advia 120s) were due for renewal, Sysmex, alone amongst the providers at that time, were able to offer an innovative solution to our workflow problems and burgeoning workload.
They became our preferred supplier and subsequently installed an HST with 2 XE-2100’s and an SP-1000 all on an automated track.
Since the installation, the workflow through the laboratory has been smoothed and streamed, such that 1 BMS and an ATO/AP can comfortably deal with the day’s routine work. The system also provides a huge capacity for growth and deals with our busiest periods with ease.
Reagent storage was one of the areas in which Sysmex scored poorly during the tendering process, as we were worried about the problems that (relatively) large volumes of numerous reagents might cause. In practise, we have over come all handling issues with ease.
The reagent supplies and distribution staff are all helpful, efficient and understanding in our times of crisis.
We in turn are able to offer the opportunity for Sysmex staff (who might otherwise never see their equipment in action) to visit the department and witness at firsthand how our combined endeavours, aid the diagnosis and management of disease in our community.”
Peter Eales
Chief Biomedical Scientist, Haematology
